Clinical-stage cancer immunotherapy firm Compugen's Q3 net loss widens
I'm PortAI, I can summarize articles.
Compugen reported a Q3 revenue of $1.9 million, exceeding analyst expectations but down from the previous year. The net loss widened to $6.98 million compared to a profit last year. The company expects its cash reserves to sustain operations until Q3 2027 and is advancing its GS-0321 trial licensed to Gilead. Analysts maintain a strong buy rating, with a median 12-month price target of $4.00, reflecting a potential upside of 59.5% from its recent closing price of $1.62.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments